TY - JOUR AU - Jeimy, Samira AU - Basharat, Pari AU - Lovegrove, Fiona PY - 2019 DA - 2019/01/17 TI - Dermatomyositis associated with omalizumab therapy for severe asthma: a case report JO - Allergy, Asthma & Clinical Immunology SP - 4 VL - 15 IS - 1 AB - Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also been described; however, their relationship to the drug remains uncertain, and the frequency is unknown. SN - 1710-1492 UR - https://doi.org/10.1186/s13223-019-0319-4 DO - 10.1186/s13223-019-0319-4 ID - Jeimy2019 ER -